-
1.发明公开公开(公告)号：US20240238342A1
公开(公告)日：2024-07-18
申请号：US18574219
申请日：2022-06-27
IPC分类号： A61K35/17 , A61K31/45 , A61K39/00 , A61P35/00 , C07K14/535
CPC分类号： A61K35/17 , A61K31/45 , A61K39/4612 , A61K39/464436 , A61P35/00 , C07K14/535 , A61K2239/38 , A61K2239/48
摘要： A vaccine composition is described that is composed of 3 cells lines, the U266, H929, and K562. Methods are described for using the vaccine composition in methods of immunizing against plasma cell disorders, including multiple myeloma and related disorders.
-
公开(公告)号：US20240180968A1
公开(公告)日：2024-06-06
申请号：US18494468
申请日：2023-10-25
发明人： James Gavin , Michael Curley , Lan Cao
CPC分类号： A61K35/17 , A61K39/4613 , A61K39/4631 , A61K39/464429 , A61P35/02 , C07K16/2896 , A61K2239/13 , A61K2239/21 , A61K2239/22 , A61K2239/38 , A61K2239/48
摘要： The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US20240156962A1
公开(公告)日：2024-05-16
申请号：US18499720
申请日：2023-11-01
发明人： Lida PACAUD , Muhammad AKRAM , Dong GENG , Jordan SCHECTER , Carolyn Chang JACKSON , Enrique ZUDAIRE UBANI , Deepu MADDURI
IPC分类号： A61K39/00 , A61P35/00 , C12Q1/6886
CPC分类号： A61K39/464417 , A61K39/4611 , A61K39/4631 , A61P35/00 , C12Q1/6886 , A61K2239/38 , A61K2239/48 , C12Q2600/106 , C12Q2600/118
摘要： A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.
-
公开(公告)号：US20240041929A1
公开(公告)日：2024-02-08
申请号：US18365950
申请日：2023-08-04
发明人： Brian Joshua BELMONT , Kimberly HARRINGTON , Cyr Clovis Chua DE IMUS , Jon Christopher JONES , Eric William JEFFERY , Yeonjoo OH , Heather STRIEGEL
IPC分类号： A61K35/17 , C07K16/28 , C12N15/86 , A61K39/00 , A61P35/00 , A61K31/7076 , A61K31/675 , A61K31/4184
CPC分类号： A61K35/17 , C07K16/2878 , C12N15/86 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61P35/00 , A61K31/7076 , A61K31/675 , A61K31/4184 , A61K2239/38 , A61K2239/22 , A61K2239/21 , A61K2239/17 , A61K2239/13 , A61K2239/29 , A61K2239/48
摘要： Provided are chimeric antigen receptors (CARs), which contain extracellular antigen-binding domains that bind to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and B-cell maturation antigen (BCMA). The disclosure further relates to genetically engineered cells expressing such CARs, and uses thereof in adoptive cell therapy.
-
公开(公告)号：US20240000836A1
公开(公告)日：2024-01-04
申请号：US18039420
申请日：2021-12-03
发明人： Jordan Mark SCHECTER , Xiaohu FAN
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61P35/00 , A61K2039/505 , A61K2239/11 , A61K2239/21 , A61K2239/22 , A61K2239/31 , A61K2239/38
摘要： Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
-
6.发明公开公开(公告)号：US20230398147A1
公开(公告)日：2023-12-14
申请号：US18026505
申请日：2021-09-15
发明人： Adam B. MCCULLOUGH , Hosein KOUROS-MEHR , Peter KUFER , Mark SALVATI , Alexander C. MINELLA , Dirk NAGORSEN , Vijay UPRETI , Mukul MINOCHA , Brett HOUK
CPC分类号： A61K35/17 , C07K16/2809 , A61P35/00 , C07K14/8103 , A61K39/4611 , C12Y304/17021 , A61K2239/13 , A61K2239/58 , A61K2239/38 , A61K2239/31
摘要： The present invention relates to methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer in a patient. The administration methods reduce the incidence and/or severity of adverse events, such as cytokine release syndrome, and entail administering to a patient a priming dose of the bispecific T-cell engaging molecule by continuous intravenous infusion over a period of days followed by administration of a therapeutic dose of the bispecific T-cell engaging molecule by a bolus intravenous infusion at dosing intervals of at least a week.
-
7.发明公开公开(公告)号：US20230241212A1
公开(公告)日：2023-08-03
申请号：US18002714
申请日：2021-06-30
发明人： Yongkun Yang , Guang Hu , Taochao Tan , Zhenyu Dai , Panpan Niu , Guangrong Meng , Wei Cheng , Xiangyin Jia , Jialu Mo , Wen Wang , Bailu Xie , Junfeng Yang , Fei Zhou
IPC分类号： A61K39/00 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/02
CPC分类号： A61K39/4611 , C07K16/2803 , C07K14/70578 , C07K14/7051 , A61K39/4631 , A61K39/4643 , A61P35/02 , C07K2317/31 , C07K2319/02 , C07K2319/03 , A61K2239/13 , A61K2239/21 , A61K2239/22 , A61K2239/29 , A61K2239/38
摘要： Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.
-
公开(公告)号：US20240358829A1
公开(公告)日：2024-10-31
申请号：US18683814
申请日：2022-08-31
IPC分类号： A61K39/00 , A61K31/573 , A61P35/00 , A61P35/02 , A61P37/04 , C12N5/0783
CPC分类号： A61K39/4613 , A61K31/573 , A61P35/00 , A61P35/02 , A61P37/04 , C12N5/0646 , A61K2239/38
摘要： This invention pertains to a novel population of lymphocytes, methods for producing these, and their use in the treatment of diseases.
-
公开(公告)号：US20240307437A1
公开(公告)日：2024-09-19
申请号：US18262365
申请日：2022-01-28
IPC分类号： A61K35/17 , A61K31/517 , A61K31/675 , A61K31/7076 , A61K38/20 , A61K39/00 , C07K14/54 , C07K14/55 , C07K16/28 , C12N5/0783 , C12N9/22 , C12N15/11 , C12N15/86
CPC分类号： A61K35/17 , A61K31/517 , A61K31/675 , A61K31/7076 , A61K38/2013 , A61K38/208 , A61K38/2086 , A61K39/4611 , A61K39/46444 , C07K14/5434 , C07K14/5443 , C07K14/55 , C07K16/2875 , C07K16/2878 , C12N5/0636 , C12N9/22 , C12N15/111 , C12N15/86 , A61K2239/13 , A61K2239/21 , A61K2239/38 , C12N2310/20 , C12N2501/2302 , C12N2740/15043
摘要： Provided herein are compositions and methods for the treatment of cancers using modified TILs, wherein the modified TILs include one or more immunomodulatory agents (e.g. cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a localized immunostimulatory effect that can advantageously enhance TIL survival, proliferation and/or anti-tumor activity in a patient recipient. As such, the compositions and methods disclosed herein provide effective cancer therapies.
-
公开(公告)号：US20240285762A1
公开(公告)日：2024-08-29
申请号：US18590598
申请日：2024-02-28
发明人： Michael MALDONADO , Nikolay DELEV , Ashley KOEGEL , Susana BARRIGA FALCON , Steven Marc GREENBERG , Michael BURGESS
CPC分类号： A61K39/464412 , A61K39/4611 , A61K39/4631 , A61P37/02 , A61K2239/38
摘要： Provided herein are adoptive cell therapy methods and uses involving the administration of a dose of T cells expressing a CD19-directed chimeric antigen receptor for treating subjects with Systemic autoimmune disease and related methods, compositions, uses and articles of manufacture.
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.018 秒)
